Equities

Chongqing Genrix Biopharmaceutical Co Ltd

688443:SHH

Chongqing Genrix Biopharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)31.00
  • Today's Change-0.92 / -2.88%
  • Shares traded1.95m
  • 1 Year change-10.71%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform3
Hold0
Sell0
Strong Sell0

Share price forecast in CNY

The one analyst offering a 12 month price target expects Chongqing Genrix Biophrmctcl Co Ltd share price to rise to 40.00 in the next year from the last price of 31.00.
High29.0%40.00
Med29.0%40.00
Low29.0%40.00

Earnings history & estimates in CNY

Chongqing Genrix Biophrmctcl Co Ltd reported annual 2023 losses of -2.50 per share on Feb 23, 2024.
More ▼

Revenue history & estimates in CNY

Chongqing Genrix Biophrmctcl Co Ltd had revenues for the full year 2023 of 1.21m. Last year the company did not report any revenues.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.